
Alzheimer’s disease is more than age-related memory loss—it’s a serious brain disorder. In this episode of the Swiss Connection Science podcast, Swissinfo healthcare reporter Jessica Davis Pluess explores the science, hope, and controversy surrounding new Alzheimer’s drugs like Leqembi and Kisunla. With billions invested and global regulatory decisions diverging, what do these treatments mean for patients and healthcare systems?
Visit SWI swissinfo.ch for more on this topic and a video on this story. Please come to SWI swissinfo.ch for more of our science stories from Switzerland.
Journalist: Jessica Davis Plüss
Host: Jo Fahy
Audio editor/video journalist: Michele Andina
Distribution and Marketing: Xin Zhang
SWI swissinfo.ch is a public service media company based in Bern, Switzerland.
Fler avsnitt från "The Swiss Connection"



Missa inte ett avsnitt av “The Swiss Connection” och prenumerera på det i GetPodcast-appen.







